# Tocilizumab for the Treatment of Behcet's Syndrome

> **NCT01693653** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 1 (actual)

## Conditions studied

- Behcet Syndrome

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01693653
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693653, "Tocilizumab for the Treatment of Behcet's Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01693653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*